Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic study of crizotinib in Japanese patients with ALK fusion gene positive Non-small cell carcinoma

Trial Profile

Pharmacokinetic study of crizotinib in Japanese patients with ALK fusion gene positive Non-small cell carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 27 Feb 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 12 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top